Sobi grants Japanese rights on two drugs to Asahi Kasei
Japanese medium-sized drugmaker Asahi Kasei Pharma yesterday revealed it has acquired the exclusive distribution rights in Japan for two products developed by Swedish Orphan Biovitrum (STO: SOBI). Financial terms of the agreement were not disclosed.
The drugs are pegcetacoplan, a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), and avatrombopag, an agent for improving thrombocytopenia associated with chronic liver disease.
Pegcetacoplan is a PEGylated peptide inhibiting the function of complement protein C3, which triggers hemolysis (breaking down of red blood cells), and has been approved as a therapeutic drug for PNH in the USA and Europe. It is sold as Empaveli in the USA by Apellis Pharmaceuticals (Nasdaq: APLS) and as Aspaveli in Europe by Swedish Orphan Biovitrum (also known as Sobi). In Japan, an application has been filed for approval of its manufacture and sale.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze